ID   GIST430B
AC   CVCL_A9N1
DR   cancercelllines; CVCL_A9N1
DR   GEO; GSM2527266
DR   GEO; GSM2527267
DR   Wikidata; Q102113883
RX   PubMed=29866822;
RX   PubMed=30488756;
CC   Characteristics: Has lost KIT protein expression (PubMed=30488756).
CC   Selected for resistance to: ChEBI; CHEBI_45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Mutation; HGNC; HGNC:6342; KIT; Simple; p.Val560_Leu576del (c.1678_1728del); ClinVar=VCV000523644; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6342; KIT; Simple; p.Val654Ala (c.1961T>C); ClinVar=VCV000375921; Zygosity=Heterozygous (from parent cell line).
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Cell type: Interstitial cell of Cajal; CL=CL_0002088.
DI   NCIt; C3868; Gastrointestinal stromal tumor
DI   ORDO; Orphanet_44890; Gastrointestinal stromal tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_7040 ! GIST430
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 19-12-24; Version: 7
//
RX   PubMed=29866822; DOI=10.1073/pnas.1802079115; PMCID=PMC6016782;
RA   Hemming M.L., Lawlor M.A., Zeid R., Lesluyes T., Fletcher J.A.,
RA   Raut C.P., Sicinska E.T., Chibon F., Armstrong S.A., Demetri G.D.,
RA   Bradner J.E.;
RT   "Gastrointestinal stromal tumor enhancers support a transcription
RT   factor network predictive of clinical outcome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:E5746-E5755(2018).
//
RX   PubMed=30488756; DOI=10.1080/15384101.2018.1553335; PMCID=PMC6300111;
RA   Tu Y.-Q., Zuo R., Ni N., Eilers G., Wu D.-L., Pei Y.-T., Nie Z.-M.,
RA   Wu Y.-Q., Wu Y.-H., Ou W.-B.;
RT   "Activated tyrosine kinases in gastrointestinal stromal tumor with
RT   loss of KIT oncoprotein expression.";
RL   Cell Cycle 17:2577-2592(2018).
//